Àüü : 301°Ç
¹®¼¹øÈ£ / ¿äÁö(Á¦¸ñ) |
---|
EECS/0123-11, 2023.05.17 ±ÝÀ¶ÀÚ»êÀÇ ÀçºÐ·ù (2) (Reclassification of financial assets) |
EECS/0123-10, 2023.05.17 ±ÝÀ¶ÀÚ»êÀÇ ÀçºÐ·ù (1) (Reclassification of financial assets) |
EECS/0123-09, 2023.05.17 ±ÝÀ¶»óÇ°ÀÇ ½Å¿ëÀ§Çè °ø½Ã (Credit risk disclosures for financial instruments) |
EECS/0123-08, 2023.05.17 ±âÈÄ °ü·Ã À§Çè °ø½Ã (Climate risk disclosures in financial statements) |
EECS/0123-07, 2023.05.17 ¼Õ»ó°Ë»ç ½Ã ¹Ý¿µµÈ ±âÈÄ °ü·Ã À§Çè °ø½Ã (Climate risk disclosures in impairment tests) |
EECS/0123-06, 2023.05.17 ¼öÀÍÀÇ ±¸ºÐ °ø½Ã (Disaggregation of revenue) |
EECS/0123-05, 2023.05.17 ¸®½º·á °ø½Ã (Lease payments disclosures) |
EECS/0123-04, 2023.05.17 ºñÈÆó¼ºÀÚ»êÀÇ ±³È¯ (Exchange of non-monetary assets) |
EECS/0123-03, 2023.05.17 Á¦¾àȸ»ç¿¡¼ ³»ºÎÀûÀ¸·Î âÃâÇÑ ¹«ÇüÀÚ»ê ÀÎ½Ä (Recognition of an internally generated intangible asset in a pharmaceutical project) |
EECS/0123-02, 2023.05.17 µÑ ÀÌ»óÀÇ ¿µ¾÷ºÎ¹®À» ÇϳªÀÇ ¿µ¾÷ºÎ¹®À¸·Î ÅëÇÕ (Aggregation of several operating segments into one reporting segment) |
½Ç¹«Çؼ³
- Åýº³Ý [»ýÈ°¹ý·É Q&A] ÅðÁ÷±Þ¿©Á¦µµ
- Åýº³Ý [ÁÖ°£ HOT »ó´ã»ç·Ê] °¡¾÷»ó¼Ó°øÁ¦ ÀçÁ÷¿ä°Ç¿¡¼ »ó¼ÓÀÎÀÌ ´Ù¸¥ »ç¾÷ÀåÀ» â¾÷ÇÏ´Â µî °â¾÷Çصµ µÇ´ÂÁö? ¿Ü
- º¯Á¾È 2024³âºÎÅÍ »õ·Î Àû¿ëµÇ´Â È¥ÀΤýÃâ»ê Áõ¿©Àç»ê °øÁ¦
- ±è¹ü¼® ´ç½ÅÀÌ ¾Ë°í ÀÖ´Â ¿µ¾÷ÀÌÀÍ, ±× ¿µ¾÷ÀÌÀÍÀÌ ¸Â½À´Ï±î?(1) - ¼ÕÀÍ°è»ê¼ÀÇ ±¸Á¶
- ¾È¹ü¼ö Àú¼º°úÀÚ¿¡ ´ëÇÑ Åë»óÇØ°íÀÇ Á¤´ç¼º
- Åýº³Ý [»ýÈ°¹ý·É Q&A] ÅðÁ÷±Þ¿©Á¦µµ
- Åýº³Ý [ÁÖ°£ HOT »ó´ã»ç·Ê] °¡¾÷»ó¼Ó°øÁ¦ ÀçÁ÷¿ä°Ç¿¡¼ »ó¼ÓÀÎÀÌ ´Ù¸¥ »ç¾÷ÀåÀ» â¾÷ÇÏ´Â µî °â¾÷Çصµ µÇ´ÂÁö? ¿Ü
- º¯Á¾È 2024³âºÎÅÍ »õ·Î Àû¿ëµÇ´Â È¥ÀΤýÃâ»ê Áõ¿©Àç»ê °øÁ¦
- ±è¹ü¼® ´ç½ÅÀÌ ¾Ë°í ÀÖ´Â ¿µ¾÷ÀÌÀÍ, ±× ¿µ¾÷ÀÌÀÍÀÌ ¸Â½À´Ï±î?(1) - ¼ÕÀÍ°è»ê¼ÀÇ ±¸Á¶
- ¾È¹ü¼ö Àú¼º°úÀÚ¿¡ ´ëÇÑ Åë»óÇØ°íÀÇ Á¤´ç¼º
Hot issue